ImmunityBio (IBRX) Debt to Equity (2016 - 2025)
ImmunityBio (IBRX) has disclosed Debt to Equity for 12 consecutive years, with -$0.65 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity fell 11.55% to -$0.65 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.65, a 11.55% decrease, with the full-year FY2025 number at -$0.65, down 11.55% from a year prior.
- Debt to Equity was -$0.65 for Q4 2025 at ImmunityBio, down from -$0.6 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$0.15 in Q3 2024 to a low of -$2.0 in Q2 2021.
- A 5-year average of -$0.77 and a median of -$0.6 in 2025 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: plummeted 4025.26% in 2021, then skyrocketed 87.22% in 2024.
- ImmunityBio's Debt to Equity stood at -$1.64 in 2021, then surged by 59.16% to -$0.67 in 2022, then skyrocketed by 60.45% to -$0.27 in 2023, then tumbled by 119.23% to -$0.58 in 2024, then dropped by 11.55% to -$0.65 in 2025.
- Per Business Quant, the three most recent readings for IBRX's Debt to Equity are -$0.65 (Q4 2025), -$0.6 (Q3 2025), and -$0.54 (Q2 2025).